Evidence map›Paper›PMID 38286962›Full record

ArticleAdvances in therapy2024

Can the Evidence-Based Use of Probiotics (Notably Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG) Mitigate the Clinical Effects of Antibiotic-Associated Dysbiosis?

Dan Waitzberg, Francisco Guarner, Iva Hojsak, Gianluca Ianiro, D Brent Polk, Harry Sokol

Open access · hybridAbstract read
In one paragraph

Article in Advances in therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 25 citations in OpenAlex.

  1. [Preventive effect ofZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026
    Trial
  2. Metabolic Engineering of ProbioticFoods (Basel, Switzerland) · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Antioxidant and Anti-Inflammatory Activities of Probiotic Strains.International journal of molecular sciences · 2026
    Review
  12. Review
  13. Article
  14. Review
  15. Frontiers in immunology · 2026
    Article
  16. Article
  17. Article
  18. Adjunctive use ofTranslational gastroenterology and hepatology · 2026
    Article
  19. Gut microbes · 2025
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 6 countries.

Dan WaitzbergDepartment of Gastroenterology, LIM-35, School of Medicine, University of São Paulo, São Paulo, Brazil.ORCID 0000-0002-9196-9372
Francisco GuarnerTeknon Medical Centre, Barcelona, Spain.ORCID 0000-0002-4051-0836
Iva HojsakReferral Centre for Pediatric Gastroenterology and Nutrition, School of Medicine, University of Zagreb, Zagreb, Croatia.ORCID 0000-0003-3262-5964
Gianluca IaniroDepartment of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.ORCID 0000-0002-8318-0515
D Brent PolkDivision of Pediatric Gastroenterology, Hepatology, and Nutrition, San Diego, and Rady Children's Hospital, University of California, San Diego, CA, USA.ORCID 0000-0001-6680-1554
Harry SokolGastroenterology Department, Saint-Antoine Hospital, Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, 184 Rue du Faubourg Saint-Antoine, 75571, Paris Cedex 12, France. harry.sokol@gmail.com.ORCID 0000-0002-2914-1822
Hospital Quirón Teknon · ESInserm · FRUniversidade de São Paulo · BRUniversità Cattolica del Sacro Cuore · ITUniversity of California San Diego · USUniversity of Zagreb · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dysbiosis corresponds to the disruption of a formerly stable, functionally complete microbiota. In the gut, this imbalance can lead to adverse health outcomes in both the short and long terms, with a potential increase in the lifetime risks of various noncommunicable diseases and disorders such as atopy (like asthma), inflammatory bowel disease, neurological disorders, and even behavioural and psychological disorders. Although antibiotics are highly effective in reducing morbidity and mortality in infectious diseases, antibiotic-associated diarrhoea is a common, non-negligible clinical sign of gut dysbiosis (and the only visible one). Re-establishment of a normal (functional) gut microbiota is promoted by completion of the clinically indicated course of antibiotics, the removal of any other perturbing external factors, the passage of time (i.e. recovery through the microbiota's natural resilience), appropriate nutritional support, and-in selected cases-the addition of probiotics. Systematic reviews and meta-analyses of clinical trials have confirmed the strain-specific efficacy of some probiotics (notably the yeast Saccharomyces boulardii CNCM I-745 and the bacterium Lactobacillus rhamnosus GG) in the treatment and/or prevention of antibiotic-associated diarrhoea in children and in adults. Unusually for a probiotic, S. boulardii is a eukaryote and is not therefore directly affected by antibiotics-making it suitable for administration in cases of antibiotic-associated diarrhoea. A robust body of evidence from clinical trials and meta-analyses shows that the timely administration of an adequately dosed probiotic (upon initiation of antibiotic treatment or within 48 h) can help to prevent or resolve the consequences of antibiotic-associated dysbiosis (such as diarrhoea) and promote the resilience of the gut microbiota and a return to the pre-antibiotic state. A focus on the prescription of evidence-based, adequately dosed probiotics should help to limit unjustified and potentially ineffective self-medication.

Indexed as

Lacticaseibacillus rhamnosusProbioticsSaccharomyces boulardiiAdultAnti-Bacterial AgentsChildDiarrheaDysbiosisHumansMeta-Analysis as TopicSaccharomyces cerevisiaeSystematic Reviews as TopicAnti-Bacterial AgentsAntibioticsDiarrhoeaDoseDysbiosisProbioticsStrain-specificity

Identifiers

PMID38286962
PMCPMC10879266
OpenAlexW4391329629

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.